Schonfeld Strategic Advisors’s OptimizeRx OPRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$469K	Sell	74,761 -23,409	-24%	-$217K	﹤0.01%	1411
2025 Q4	$1.2M	Buy	98,170 +36,522	+59%	+$597K	0.01%	1053
2025 Q3	$1.26M	Sell	61,648 -181,995	-75%	-$2.89M	0.01%	1277
2025 Q2	$3.29M	Buy	243,643 +121,619	+100%	+$1.33M	0.02%	739
2025 Q1	$1.06M	Buy	+122,024	New	+$746K	0.01%	1263
2022 Q1	–	Sell	-6,073	Closed	-$378K	–	2825
2021 Q4	$378K	Buy	+6,073	New	+$460K	﹤0.01%	1411

Other funds holding OPRX

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schonfeld Strategic Advisors's OPRX Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its OptimizeRx (OPRX) stake by 24% in Q1 2026, selling an estimated $217K and leaving 74,761 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.

Schonfeld Strategic Advisors first reported a position in OPRX in Q4 2021 and has held it in 6 quarters since. The position peaked at $3.29M in Q2 2025. 128 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

Schonfeld Strategic Advisors held 74,761 shares of OptimizeRx worth $469K as of Q1 2026.
Schonfeld Strategic Advisors sold 23,409 OptimizeRx shares in Q1 2026, an estimated $217K.
OptimizeRx made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1411 holding.
Schonfeld Strategic Advisors first reported a position in OptimizeRx in Q4 2021 and has held it in 6 quarters since.
Schonfeld Strategic Advisors's OptimizeRx position peaked at $3.29M in Q2 2025.
128 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.